Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib plus /- Radiation Therapy in a Real-World Canadian Cohort

被引：0
|
作者：
Litt, I. [1 ]
Gibson, A. [2 ]
Dean, M. [2 ]
Elegbede, A. [2 ]
Bebb, G. [2 ]
Cheung, W. [1 ]
Pabani, A. [1 ]
机构：
[1] Alberta Hlth Serv, Calgary, AB, Canada
[2] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Non-small cell lung cancer; Targeted Therapies; Brain Metastases;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S434
页数：1
相关论文
共 50 条
  • [31] Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy
    Guo, Tiantian
    Ni, Jianjiao
    Yang, Xi
    Li, Yuan
    Li, Yida
    Zou, Liqing
    Wang, Shengping
    Liu, Quan
    Chu, Li
    Chu, Xiao
    Li, Shuyan
    Ye, Luxi
    Zhu, Zhengfei
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 107 (01): : 62 - 71
  • [32] Osimertinib combined with chemotherapy as fi rst-line treatment in EGFR-mutant advanced NSCLC patients: The fi rst real-world analysis in China
    Ji, W.
    Yu, Y.
    Ai, X.
    Chen, Z.
    Zhou, Z.
    Li, Z.
    ANNALS OF ONCOLOGY, 2024, 35
  • [33] Real-World Rates of Infusion-Related Reactions in Patients with EGFR-Mutant NSCLC Receiving Amivantamab
    Gupta, D. M.
    Chang, C.
    Wendt, L.
    Mohindra, N.
    Chae, Y.
    Tobben, D.
    Gharzai, L. A.
    Patel, J. D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S713 - S713
  • [34] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [35] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [36] Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
    Wan-Ling Tan
    Quan Sing Ng
    Cindy Lim
    Eng Huat Tan
    Chee Keong Toh
    Mei-Kim Ang
    Ravindran Kanesvaran
    Amit Jain
    Daniel S. W. Tan
    Darren Wan-Teck Lim
    BMC Cancer, 18
  • [37] LTreatment sequencing in NSCLC EGFR plus - real-world data
    Fernandes, Ana Luisa
    Dias, Margarida
    Coutinho, Daniel
    Silva, Eloisa
    Costa, Telma
    Campainha, Sergio
    Conde, Sara
    Barroso, Ana
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [38] A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
    Lee, Jiyun
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : E14 - E14
  • [39] Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
    Ma, J.
    Li, Y.
    Lai, G. G. Y.
    Tan, E-H.
    Lim, W. D. T.
    Ang, M-K.
    Ng, Q. S.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Fong, K. W.
    Siow, T. R.
    Thiagarajan, A.
    Yap, S. P.
    Chia, S. H. B.
    Ng, W. L.
    Tan, D. S. W.
    Tan, S. H.
    Tan, W. L.
    Chua, K. L. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S970 - S970
  • [40] Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
    Tan, Wan-Ling
    Ng, Quan Sing
    Lim, Cindy
    Tan, Eng Huat
    Toh, Chee Keong
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Jain, Amit
    Tan, Daniel S. W.
    Lim, Darren Wan-Teck
    BMC CANCER, 2018, 18
12345